SG11201507328RA - Yeast-based immunotherapy for chordoma - Google Patents

Yeast-based immunotherapy for chordoma

Info

Publication number
SG11201507328RA
SG11201507328RA SG11201507328RA SG11201507328RA SG11201507328RA SG 11201507328R A SG11201507328R A SG 11201507328RA SG 11201507328R A SG11201507328R A SG 11201507328RA SG 11201507328R A SG11201507328R A SG 11201507328RA SG 11201507328R A SG11201507328R A SG 11201507328RA
Authority
SG
Singapore
Prior art keywords
chordoma
yeast
based immunotherapy
immunotherapy
Prior art date
Application number
SG11201507328RA
Inventor
Timothy C Rodell
David Apelian
Claudia Palena
Jeffrey Schlom
Original Assignee
Globeimmune Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc, Us Health filed Critical Globeimmune Inc
Publication of SG11201507328RA publication Critical patent/SG11201507328RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11201507328RA 2013-03-19 2014-03-19 Yeast-based immunotherapy for chordoma SG11201507328RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361803332P 2013-03-19 2013-03-19
PCT/US2014/031183 WO2014186047A1 (en) 2013-03-19 2014-03-19 Yeast-based immunotherapy for chordoma

Publications (1)

Publication Number Publication Date
SG11201507328RA true SG11201507328RA (en) 2015-10-29

Family

ID=51898771

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201507328RA SG11201507328RA (en) 2013-03-19 2014-03-19 Yeast-based immunotherapy for chordoma
SG10201707608QA SG10201707608QA (en) 2013-03-19 2014-03-19 Yeast-based immunotherapy for chordoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201707608QA SG10201707608QA (en) 2013-03-19 2014-03-19 Yeast-based immunotherapy for chordoma

Country Status (15)

Country Link
US (2) US10507235B2 (en)
EP (1) EP2976100B1 (en)
JP (1) JP6509808B2 (en)
KR (1) KR20150132867A (en)
CN (1) CN105228646B (en)
AU (1) AU2014265873B2 (en)
BR (1) BR112015023968A2 (en)
CA (1) CA2907560C (en)
HK (1) HK1216861A1 (en)
IL (1) IL241384B (en)
MX (1) MX2015013380A (en)
RU (1) RU2679806C2 (en)
SG (2) SG11201507328RA (en)
TW (2) TW201936206A (en)
WO (1) WO2014186047A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3051449A1 (en) * 2015-01-29 2016-08-03 Bayer Technology Services GmbH Computer-implemented method for creating a fermentation model
JP7048482B2 (en) 2015-08-03 2022-04-05 アメリカ合衆国 Brachyury deletion variants, non-yeast vectors encoding Brachyury deletion variants, and their use
KR20180054587A (en) * 2015-08-03 2018-05-24 글로브이뮨 Modified yeast-brachyury immunotherapeutic composition

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (en) 1980-07-09 1986-05-30 Univablot MEDICINAL PRODUCTS BASED ON YEAST OR THEIR INSOLUBLE EXTRACTS
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
CA2346735C (en) * 1997-10-10 2005-01-25 Meyer Pharmaceuticals, Llc Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
KR101455222B1 (en) 2002-12-16 2014-10-31 글로브이뮨 Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20060009404A1 (en) 2004-07-09 2006-01-12 Williams Jason R Tumor ablation in combination with pharmaceutical compositions
US20100034840A1 (en) 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CA2638815A1 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
BRPI0709340A2 (en) 2006-03-27 2013-04-16 Globeimmune Inc mutations and compositions and methods of use thereof
SG10201405420QA (en) 2007-02-02 2014-10-30 Globeimmune Inc Methods for producing yeast-based vaccines
EP2444410A3 (en) * 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
CA2681246A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
MA34956B1 (en) 2011-02-12 2014-03-01 Globeimmune Inc THERAPY WITH YEAST FOR CHRONIC INFECTION WITH HEPATITIS B
CN103648513B (en) 2011-03-17 2018-10-12 全球免疫股份有限公司 Yeast-Brachyury (Brachyury) immunotherapeutic composition
BR112013032381B1 (en) 2011-06-14 2021-01-12 Globeimmune, Inc. yeast-based compositions and methods for treating or preventing infection by the hepatitis delta virus
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
KR20180054587A (en) 2015-08-03 2018-05-24 글로브이뮨 Modified yeast-brachyury immunotherapeutic composition

Also Published As

Publication number Publication date
BR112015023968A2 (en) 2017-08-22
KR20150132867A (en) 2015-11-26
CN105228646A (en) 2016-01-06
US10507235B2 (en) 2019-12-17
EP2976100A1 (en) 2016-01-27
RU2679806C2 (en) 2019-02-13
JP6509808B2 (en) 2019-05-08
AU2014265873B2 (en) 2019-01-17
EP2976100A4 (en) 2016-10-19
CA2907560A1 (en) 2014-11-20
JP2016516081A (en) 2016-06-02
CA2907560C (en) 2021-12-07
US20160271238A1 (en) 2016-09-22
AU2014265873A1 (en) 2015-10-22
SG10201707608QA (en) 2017-10-30
IL241384B (en) 2019-12-31
IL241384A0 (en) 2015-11-30
TW201936206A (en) 2019-09-16
EP2976100B1 (en) 2020-07-01
WO2014186047A1 (en) 2014-11-20
US20200046818A1 (en) 2020-02-13
CN105228646B (en) 2021-04-06
MX2015013380A (en) 2016-01-08
TW201446261A (en) 2014-12-16
HK1216861A1 (en) 2016-12-09
TWI674108B (en) 2019-10-11
RU2015144511A (en) 2017-05-03
WO2014186047A8 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
HK1224312A1 (en) Novel compounds
HK1217023A1 (en) Novel antibodies
IL246002A0 (en) Novel methods
HK1217337A1 (en) Tau immunotherapy tau
HK1222393A1 (en) Novel quinoline-substituted compound
GB201311910D0 (en) Novel Compounds
GB201311888D0 (en) Novel compounds
GB201317363D0 (en) Novel compounds
GB201312133D0 (en) Immunotherapy
GB201318222D0 (en) Novel compounds
GB201314926D0 (en) Novel Compounds
GB201322512D0 (en) Novel compounds
HK1216861A1 (en) Yeast-based immunotherapy for chordoma
GB201320021D0 (en) Novel Compounds
HK1218746A1 (en) Novel compounds
GB201316762D0 (en) Novel compounds
GB201316764D0 (en) Novel compounds
GB201401185D0 (en) Novel compounds
GB201321975D0 (en) Novel compounds
GB201321977D0 (en) Novel compounds
GB201321976D0 (en) Novel compounds
GB201321972D0 (en) Novel compounds
GB201321811D0 (en) Novel compounds
GB201319354D0 (en) Novel compounds
GB201316100D0 (en) Novel compounds